Along these lines, it was shown that HDAC3 selective inhibitors given to counteract HDAC3 antagonism of CREBBP, recruited T cells into murine GCB-DLBCLs in vivo and enhanced the anti-tumor efficacy of checkpoint blockade63. The gene discussed is CREBBP; the disease is neoplasm.